Sarcoidosis Clinical Trial
Official title:
Validation of the Analysis Methodology Behind the Use of Quantitative 2-deoxy-2-[Fluorine-18] Fluoro-D-glucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) to Assess Lung Inflammation
The purpose of this study is to validate the method of analysing Positron Emission Tomography
(PET) images to assess lung inflammation. Development of novel therapeutic drugs requires a
biomarker which is sensitive to the underlying disease and can respond to therapeutic
interventions. PET is a potential imaging biomarker which can target molecular and cellular
processes. There is currently no standardised method of analysing PET lung data and a lack of
validation for the existing techniques.
This study is divided in to two parts. Part A aims to determine the best method to perform
18F-FDG PET/CT lung analysis and how it correlates with cell counts from bronchoalveolar
lavage (BAL) samples taken from participants with active pulmonary sarcoidosis.
Part B will compare imaging data from healthy volunteers who have either undergone a
Lipopolysaccharide (LPS) challenge (whereby the lung is temporarily inflamed) or saline
equivalent to determine whether lung inflammation can be detected by 18F-FDG PET/CT. No
medications will be given and patients will not be asked to stop or change existing
medication.
Inflammation plays an important role in a myriad of human diseases. Interstitial Lung
Diseases (ILDs) are characterised by widespread inflammation and represent a major burden to
the health sector. Imaging offers a method of assessing lung inflammation which is
non-invasive and may help facilitate the development of new therapeutic drugs. Positron
Emission Tomography (PET) is a sensitive imaging modality that uses radioactive material to
highlight areas of disease. 18F-FDG is the most common radioactive tracer; it accumulates in
cells with an increased metabolic rate. Previous studies have shown that inflammatory cells
have an increased metabolic rate, thus PET imaging could highlight inflammation. 18F-FDG PET
has been used in many studies exploring lung diseases; the concentration of tracer is thought
to relate to the severity of inflammation.
There is currently no standardised method to analyse FDG-PET scans to assess the
concentration of tracer in the lung (and therefore inflammation). A major challenge is
providing corrections to ensure that the image only represents tracer in the lung tissue.
Such corrections are non-trivial and affect how images are interpreted. A robust validation
is needed to ensure that the analysis methods used in FDG-PET images truly represent the
degree of lung inflammation.
Part A of this study aims to validate and compare the different analysis methods. Pulmonary
sarcoidosis is a disease characterised by widespread lung inflammation. In Part A of the
study the investigators will recruit patients with this condition, as well as age and gender
matched (wherever possible) healthy volunteers. All Part A participants will receive one
dynamic 18F-FDG PET/CT scan. The investigators will assess the uptake of 18FDG from PET
images from patients with sarcoidosis versus those taken from healthy volunteers to validate
and assess the reliability of the analysis method.
For Part B of the study the investigators will recruit healthy volunteers aged 50 or more. If
sarcoidosis patients in Part A are 50 years old or more, the age-matched HV will be recruited
in to Part B instead, thus potentially minimising the number of HVs that might need to be
recruited in to Part A of the study.
The aims of this research study are:
i) To compare FDG-PET derived tissue inflammation measures against measures of inflammation
from BAL samples.
ii) To compare different models of 18F-FDG lung analysis in patients with pulmonary
sarcoidosis.
iii) To identify whether FDG PET is sensitive enough to detect a change in inflammation
induced in healthy volunteers.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04008069 -
Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
|
Phase 2 | |
Recruiting |
NCT02807025 -
Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases
|
N/A | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT00373555 -
Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis
|
N/A | |
Completed |
NCT00326534 -
Rickettsial Genesis to Sarcoidosis in Denmark
|
N/A | |
Completed |
NCT00274352 -
A Study of Adalimumab to Treat Sarcoidosis of the Skin
|
Phase 2 | |
Recruiting |
NCT00470327 -
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
|
||
Completed |
NCT00512967 -
The Occurence of Inflammation and Oxidative Stress in Lung Diseases
|
N/A | |
Recruiting |
NCT01745237 -
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
|
||
Completed |
NCT00369980 -
Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient
|
N/A | |
Completed |
NCT00379275 -
Eye and Immunogenetic Features of Sarcoidosis
|
N/A | |
Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
Completed |
NCT06396910 -
TB and Sarcoidosis Granuloma
|
||
Completed |
NCT04156789 -
Obstructive Sleep Apnoea in Sarcoidosis
|
||
Recruiting |
NCT02916459 -
EBUS-TBNA vs Flex 19G EBUS-TBNA
|
N/A | |
Recruiting |
NCT02827734 -
Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
|
||
Completed |
NCT02546388 -
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
|
N/A | |
Completed |
NCT01687517 -
Efficacy and Safety of Influenza Vaccine During Sarcoidosis
|
Phase 3 | |
Completed |
NCT01139710 -
Sarcoidosis-associated Pulmonary Hypertension
|
N/A | |
Terminated |
NCT00747461 -
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
|
Phase 4 |